---
title: "Kimberly-Clark will acquire Tylenol manufacturer Kenvue for $40 billion. Trump once warned about the risks of Tylenol"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/264069037.md"
description: "Kimberly-Clark agreed to acquire Tylenol manufacturer Kenvue for approximately $40 billion, which will position Kimberly-Clark among the leaders in the consumer health industry. The acquisition price is $21.01 per share, a 46% premium over Kenvue's closing price last Friday. This transaction faces legal and political risks, as Kenvue has clashed with the Trump administration over Tylenol safety issues. After the merger, Kimberly-Clark's revenue will reach $32 billion, making it the second-largest health product seller after Procter & Gamble. Kimberly-Clark's stock price plummeted 14%, while Kenvue's stock price opened up 20%"
datetime: "2025-11-03T17:56:42.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/264069037.md)
  - [en](https://longbridge.com/en/news/264069037.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/264069037.md)
---

> 支持的语言: [English](https://longbridge.com/en/news/264069037.md) | [繁體中文](https://longbridge.com/zh-HK/news/264069037.md)


# Kimberly-Clark will acquire Tylenol manufacturer Kenvue for $40 billion. Trump once warned about the risks of Tylenol

Kimberly-Clark has agreed to acquire the struggling Tylenol manufacturer Kenvue for approximately $40 billion, a move that will position the Scott tissue producer among the leaders in the consumer health industry.

Kimberly-Clark will acquire Kenvue at a price of $21.01 per share, representing a 46% premium over Kenvue's closing price last Friday. The two companies stated that the deal values Kenvue at approximately $48.7 billion based on enterprise value. This transaction exposes Kimberly-Clark to legal and political risks. Since Kenvue's spin-off from Johnson & Johnson in 2023, its financial condition has been poor, and it is currently embroiled in escalating confrontations with the Trump administration over safety issues related to its flagship product, Tylenol. Year-to-date, Kenvue's stock price has fallen nearly 33%.

Kimberly-Clark stated that post-merger, the company's revenue will reach $32 billion, surpassing Unilever to become the second-largest seller of health and wellness products, only behind Procter & Gamble.

Kimberly-Clark's stock plummeted 14% in New York, marking its largest single-day drop since 2000. Meanwhile, Kenvue's stock surged 20% at the open to $17.18, still below its issue price

### 相关股票

- [Procter & Gamble (PG.US)](https://longbridge.com/zh-CN/quote/PG.US.md)

## 相关资讯与研究

- [Old Spice Teams Up With Iconic R&B Group to Ignite Beloved "Mom Song" in New Campaign: 'The End of Adolescents' | PG Stock News](https://longbridge.com/zh-CN/news/278552015.md)
- [Mr. Clean Unretires and Launches New Innovation to Tackle Messes | PG Stock News](https://longbridge.com/zh-CN/news/277808973.md)
- [Here's How Much $100 Invested In Waste Management 10 Years Ago Would Be Worth Today](https://longbridge.com/zh-CN/news/280844888.md)
- [The Home Depot, Inc. $HD Shares Sold by Donaldson Capital Management LLC](https://longbridge.com/zh-CN/news/281149065.md)
- [Short Interest in Hermes International SA - Unsponsored ADR (OTCMKTS:HESAY) Drops By 34.7%](https://longbridge.com/zh-CN/news/280877138.md)